FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385186116> ?p ?o ?g. }

• W4385186116 endingPage "4318" @default.
• W4385186116 startingPage "4307" @default.
• W4385186116 abstract "Fibrosing mediastinitis (FM) is a rare proliferative disease within the mediastinum that leads to pulmonary hypertension, which has been regarded as a major cause of death. This study aims to evaluate the potential value of fibroblast activation protein inhibitor (FAPI)-PET/CT in the integration of diagnosis and treatment of FM through targeting FAPI in fibrosis rats and provide a theoretical basis for clinical management of FM patients. By performing a 18F-FAPI PET/CT scan, the presence of FAPI-avid in the fibrotic lesion was determined. Through a fibrosis rat model, 18F-FAPI-74 was used for lesion imaging and 177Lu-FAPI-46 was utilized to investigate the potential therapeutic effect on FM in vivo. In addition, biodistribution analysis and radiation dosimetry were carried out. With the 177Lu-FAPI-46 pharmacokinetic data of rats as the input, the estimated dose for female adults was computed, which can provide some useful information for the safe application of radiolabeled FAPI in the detection and treatment of FM in patients. Then, major findings on the use of FAPI PET/CT and SPECT/CT in FM were presented. 18F-FAPI-74 showed a high-level uptake in FM lesions of patients (SUVmax 7.94 ± 0.26), which was also observed in fibrosis rats (SUVmax 2.11 ± 0.23). Consistently, SPECT/CT imaging of fibrosis rats also revealed that 177Lu-FAPI-46-avid was active for up to 60 h in fibrotic lesions. In addition to this robust diagnostic performance, a possible therapeutic impact was evaluated as well. It turned out that no spontaneous healing of lesions was observed in the control group, whereas there was complete healing on day 9, day 11, and day 14 in the 30, 100, and 300 MBq groups, respectively. With a significant difference in the free of event rate in the Kaplan-Meier curve among four groups (P < 0.001), a dose of 300 MBq displayed the best therapeutic effect, and no obvious damage was observed in the kidney. Furthermore, organ-absorbed doses and an effective dose (0.4320 mSv/MBq) of 177Lu-FAPI-46 presumed for patients were assumed to give a preliminary indication of its safe use in clinical practice. In conclusion, 18F-FAPI-46 PET/CT can be a potentially valuable tool for the diagnosis of FM. Of note, 177Lu-FAPI-46 may be a novel and safe radiolabeled reagent for the integration of diagnosis and treatment of FM." @default.
• W4385186116 created "2023-07-25" @default.
• W4385186116 creator A5000260664 @default.
• W4385186116 creator A5023526691 @default.
• W4385186116 creator A5026000663 @default.
• W4385186116 creator A5035446189 @default.
• W4385186116 creator A5043774051 @default.
• W4385186116 creator A5053196671 @default.
• W4385186116 creator A5062852782 @default.
• W4385186116 creator A5069599515 @default.
• W4385186116 creator A5069923278 @default.
• W4385186116 creator A5069961516 @default.
• W4385186116 creator A5073872315 @default.
• W4385186116 creator A5074060062 @default.
• W4385186116 creator A5084303956 @default.
• W4385186116 creator A5087780600 @default.
• W4385186116 date "2023-07-24" @default.
• W4385186116 modified "2023-10-18" @default.
• W4385186116 title "Potential Value of FAPI PET/CT in the Detection and Treatment of Fibrosing Mediastinitis: Preclinical and Pilot Clinical Investigation" @default.
• W4385186116 cites W1552841480 @default.
• W4385186116 cites W1963818841 @default.
• W4385186116 cites W1976564364 @default.
• W4385186116 cites W1982055976 @default.
• W4385186116 cites W2012148132 @default.
• W4385186116 cites W2028510638 @default.
• W4385186116 cites W2032747682 @default.
• W4385186116 cites W2065522497 @default.
• W4385186116 cites W2083197755 @default.
• W4385186116 cites W2086139228 @default.
• W4385186116 cites W2110089870 @default.
• W4385186116 cites W2152673681 @default.
• W4385186116 cites W2155127143 @default.
• W4385186116 cites W2160920036 @default.
• W4385186116 cites W247354977 @default.
• W4385186116 cites W2609366559 @default.
• W4385186116 cites W2792212840 @default.
• W4385186116 cites W2927037600 @default.
• W4385186116 cites W2944059399 @default.
• W4385186116 cites W2946769304 @default.
• W4385186116 cites W3006907174 @default.
• W4385186116 cites W3019999218 @default.
• W4385186116 cites W3037670955 @default.
• W4385186116 cites W3049388089 @default.
• W4385186116 cites W3117245384 @default.
• W4385186116 cites W3167796732 @default.
• W4385186116 cites W3179223837 @default.
• W4385186116 cites W3179453745 @default.
• W4385186116 cites W3198451649 @default.
• W4385186116 cites W3202195242 @default.
• W4385186116 cites W3217498514 @default.
• W4385186116 cites W4200009642 @default.
• W4385186116 cites W4200042182 @default.
• W4385186116 cites W4200227314 @default.
• W4385186116 cites W4205628226 @default.
• W4385186116 cites W4280497551 @default.
• W4385186116 cites W4280523444 @default.
• W4385186116 cites W4281483269 @default.
• W4385186116 cites W4294276864 @default.
• W4385186116 cites W4307941913 @default.
• W4385186116 cites W4308549597 @default.
• W4385186116 cites W4309159372 @default.
• W4385186116 cites W4310027043 @default.
• W4385186116 cites W4310464027 @default.
• W4385186116 cites W4312824401 @default.
• W4385186116 cites W4313279780 @default.
• W4385186116 cites W4317840223 @default.
• W4385186116 cites W4320920393 @default.
• W4385186116 cites W4322617918 @default.
• W4385186116 doi "https://doi.org/10.1021/acs.molpharmaceut.3c00452" @default.
• W4385186116 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37486106" @default.
• W4385186116 hasPublicationYear "2023" @default.
• W4385186116 type Work @default.
• W4385186116 citedByCount "1" @default.
• W4385186116 countsByYear W43851861162023 @default.
• W4385186116 crossrefType "journal-article" @default.
• W4385186116 hasAuthorship W4385186116A5000260664 @default.
• W4385186116 hasAuthorship W4385186116A5023526691 @default.
• W4385186116 hasAuthorship W4385186116A5026000663 @default.
• W4385186116 hasAuthorship W4385186116A5035446189 @default.
• W4385186116 hasAuthorship W4385186116A5043774051 @default.
• W4385186116 hasAuthorship W4385186116A5053196671 @default.
• W4385186116 hasAuthorship W4385186116A5062852782 @default.
• W4385186116 hasAuthorship W4385186116A5069599515 @default.
• W4385186116 hasAuthorship W4385186116A5069923278 @default.
• W4385186116 hasAuthorship W4385186116A5069961516 @default.
• W4385186116 hasAuthorship W4385186116A5073872315 @default.
• W4385186116 hasAuthorship W4385186116A5074060062 @default.
• W4385186116 hasAuthorship W4385186116A5084303956 @default.
• W4385186116 hasAuthorship W4385186116A5087780600 @default.
• W4385186116 hasConcept C126838900 @default.
• W4385186116 hasConcept C142724271 @default.
• W4385186116 hasConcept C150903083 @default.
• W4385186116 hasConcept C199374082 @default.
• W4385186116 hasConcept C207001950 @default.
• W4385186116 hasConcept C2775842073 @default.
• W4385186116 hasConcept C2777807558 @default.
• W4385186116 hasConcept C2780559512 @default.
• W4385186116 hasConcept C2781156865 @default.

• next